29 results on '"Javed Mahmood"'
Search Results
2. Abstract 444: Inhibition of GPR68 signaling activated downstream of the Warburg effect induces cell death and enhances radiosensitivity in diverse cancer cell types
- Author
-
Leif R. Neitzel, Han G. Lee, Hem Shukla, Javed Mahmood, Charles H. Williams, and Charles C. Hong
- Subjects
Cancer Research ,Oncology - Abstract
Introduction: The Warburg effect, a phenomenon in which cancer cells produce energy via aerobic glycolysis, is a hallmark of cancer. A key physiological consequence of the Warburg effect is lactate secretion, which acidifies the tumor milieu, thought to confer tumor resistance to chemotherapy and radiotherapy. Yet, the molecular mechanism of this resistance is not well understood. Ogremorphin, a small molecule inhibitor of an extracellular pH sensing receptor, GPR68, was found to inhibit the growth and survival of Glioblastomas. However, the consequences of GPR68 inhibition on carcinomas alone and in combination with radiation are unclear. The aim of this study was to investigate the effect of ogremorphin alone and in combination with radiation on multiple cancer cell lines. Methods: 1) siRNA and CRISPR-interference knockdown of GPR68 in two carcinoma cell lines Panc02 (pancreatic ductal adenocarcinoma) and A549 (lung cell carcinoma). 2) Treatment of pancreatic and lung carcinomas with GPR68 inhibitor ogremorphin alone and with ionizing radiation. 3) Cell viability (MTT), clonogenic assays, and cell cycle analysis via flow cytometry were performed. 4) Lipid peroxidation study for induction of ferroptosis. The interaction between ogremorphin and radiation was evaluated using the combination index. Results: Knockdown of GPR68 had significant effects on cell survival. Exposures of ogremorphin in clonogenic assays indicated a significant effect in reducing colony size, but not on the number of colonies, in both carcinoma cell lines. Moreover, ogremorphin significantly increased the efficacy of irradiation on the reduction of colony size. Although ogremorphin had no effect on cell cycle alone, it had a synergistic increase in G2 phase cells with radiation. Finally, GPR68 inhibition indicated synergistic activity with radiation for the induction of ferroptosis. Conclusion. GPR68 inhibition induces ferroptosis in cancer cells on its own, but also synergistically with ionizing radiation. This study suggests that GPR68 is a key cancer survival pathway activated by the acidic tumor milieu/Warburg effect, and that the ogremorphin class of molecules may be suitable candidates for combination therapy in lung and pancreatic carcinoma. Citation Format: Leif R. Neitzel, Han G. Lee, Hem Shukla, Javed Mahmood, Charles H. Williams, Charles C. Hong. Inhibition of GPR68 signaling activated downstream of the Warburg effect induces cell death and enhances radiosensitivity in diverse cancer cell types [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 444.
- Published
- 2023
3. RhoA/ROCK pathway inhibitor ameliorates erectile dysfunction induced by radiation therapy in rats
- Author
-
Ravina Pandita, Shriya Kamlapurkar, Minjie Chen, Akbar Anvari, Zeljko Vujaskovic, Ali Saeed, Javed Mahmood, Paul N. Staats, Amit Sawant, Angel Zhang, and Hem D. Shukla
- Subjects
Male ,Mean arterial pressure ,medicine.medical_specialty ,RHOA ,medicine.medical_treatment ,Urology ,030218 nuclear medicine & medical imaging ,Rats, Sprague-Dawley ,Masson's trichrome stain ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Erectile Dysfunction ,Prostate ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Saline ,biology ,business.industry ,Penile Erection ,Hematology ,medicine.disease ,Rats ,Radiation therapy ,Disease Models, Animal ,Erectile dysfunction ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Quality of Life ,biology.protein ,rhoA GTP-Binding Protein ,business ,Penis - Abstract
Prostate cancer (PCa) treatment with radiation therapy (RT) has an excellent cure rate. However, Radiation-induced Erectile Dysfunction (RiED) is a common and irreversible toxicity impacting quality of life, and there is no FDA approved specific drug for RiED. We previously showed that prostate RT increased RhoA/ROCK signaling in the cavernous nerve (CN) and penile tissues, which may lead to RiED in rats. In this study, we investigated whether RhoA/ROCK pathway inhibition by a specific inhibitor called Hydroxyfasudil (HF) can improve RiED in our well-established rat model.Male Sprague-Dawley rats were randomized to the following groups: sham-RT, HF-only, RT-only, and RT + HF. Rats were either exposed to a single dose of 25 Gy prostate-confined RT or a sham procedure. 10 mg/kg HF or normal saline was injected intraperitoneally. Erectile function was evaluated by intracavernosal pressure (ICP) and mean arterial pressure (MAP) measurements at week 14 post-RT. Cavernous nerve (CN) injury was evaluated by transmission electron microscopy (TEM), and penile tissue fibrosis by Masson trichrome staining (MT).We have found that the HF treatment prior to RT showed significant (p 0.001) improvement in ICP/MAP ratio, area under the curve, and maximum ICP value, compared to RT-alone rats. Furthermore, RT + HF treated rats exhibited increased CN myelination and decreased axonal atrophy, comparted to RT-only. HF treatment showed significantly decreased penile tissue fibrosis (p 0.05) compared to RT-alone treated rats.Our results provide the first preclinical evidence that targeting RhoA/ROCK pathway by HF may provide a novel therapeutic option for the treatment of RiED.
- Published
- 2020
4. DUOX2, a New Biomarker for Disseminated Gastric Cancer’s Response to Low Dose Radiation in Mice
- Author
-
Andrew Zodda, Sheri Li, Christopher Daniel Johnstone, Mariana B Martins, Xinrong Ma, Kayla M. Tighe, Kavita Bhalla, Eduardo Solano-Gonzalez, Andrea Casildo, Palak R Parekh, Javed Mahmood, Yannick Poirier, and Rena G. Lapidus
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,gastric cancer ,Cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Dual oxidase 2 ,medicine.disease ,Article ,Radiation therapy ,Regimen ,Docetaxel ,Internal medicine ,Low Dose Radiation Therapy ,medicine ,Adenocarcinoma ,Biomarker (medicine) ,low dose radiation therapy ,Gastrointestinal cancer ,business ,RC254-282 ,medicine.drug - Abstract
Treatment options are rather limited for gastrointestinal cancer patients whose disease has disseminated into the intra-abdominal cavity. Here, we designed pre-clinical studies to evaluate the potential application of chemopotentiation by Low Dose Fractionated Radiation Therapy (LDFRT) for disseminated gastric cancer and evaluate the role of a likely biomarker, Dual Oxidase 2 (DUOX2). Nude mice were injected orthotopically with human gastric cancer cells expressing endogenous or reduced levels of DUOX2 and randomly assigned to four treatment groups: 1, vehicle alone, 2, modified regimen of docetaxel, cisplatin and 5′-fluorouracil (mDCF) for three consecutive days, 3, Low Dose- Whole Abdomen Radiation Therapy (LD-WART) (5 fractions of 0.15 Gy in three days), 4, mDCF and LD-WART. The combined regimen increased the odds of preventing cancer dissemination (mDCF + LD-WART OR = 4.16, 80% CI = 1.0, 17.29) in the DUOX2 positive tumors, while tumors expressing lower DUOX2 levels were more responsive to mDCF alone with no added benefit from LD-WART. The molecular mechanisms underlying DUOX2 effects in response to the combined regimen include NF-κB upregulation. These data are particularly important since our study indicates that about 33% of human stomach adenocarcinoma do not express DUOX2. DUOX2 thus seems a likely biomarker for potential clinical application of chemopotentiation by LD-WART.
- Published
- 2021
- Full Text
- View/download PDF
5. BIO 300, a Nanosuspension of Genistein, Mitigates Radiation-Induced Erectile Dysfunction and Sensitizes Human Prostate Cancer Xenografts to Radiation Therapy
- Author
-
Diana Newman, Isabel L. Jackson, Michael D. Kaytor, Allen A. Alexander, Zeljko Vujaskovic, Caroline Q. Connors, Rada Pavlovic, Adam J. Harvey, Javed Mahmood, and J. Eley
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Transplantation, Heterologous ,Urology ,Mice, Nude ,Genistein ,Blood Pressure ,Radiation-Protective Agents ,030218 nuclear medicine & medical imaging ,Rats, Sprague-Dawley ,Mice ,Random Allocation ,03 medical and health sciences ,chemistry.chemical_compound ,Prostate cancer ,0302 clinical medicine ,Therapeutic index ,Erectile Dysfunction ,Suspensions ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Dosing ,Radiation ,business.industry ,Penile Erection ,Prostate ,Cancer ,Drugs, Investigational ,medicine.disease ,Fibrosis ,Rats ,Transplantation ,Radiation therapy ,Disease Models, Animal ,Radiation Injuries, Experimental ,Erectile dysfunction ,Oncology ,chemistry ,Regional Blood Flow ,030220 oncology & carcinogenesis ,Nanoparticles ,business ,Penis - Abstract
To assess whether BIO 300, a synthetic genistein nanosuspension, improves the therapeutic index in prostate cancer treatment by preventing radiation-induced erectile dysfunction (ED) without reducing tumor radiosensitivity.Male Sprague-Dawley rats were exposed to 25 Gy of 220-kV prostate-confined x-rays. Animals were randomized to receive sham radiation therapy (RT), RT alone, RT with daily BIO 300 at 2 experimental dosing regimens, or RT with daily genistein. Erectile response was evaluated over time. Penile shaft tissue was harvested for histologic analyses. Murine xenograft studies using prostate cancer cell lines determined the effects of BIO 300 dosing on RT efficacy.Prostate-confined RT significantly decreased apomorphine-induced erectile response (P.05 vs sham RT). Erection frequency in animals receiving prophylactic treatment with BIO 300 starting 3 days before RT was similar to sham controls after RT. Treatment with synthetic genistein did not mitigate loss in erectile frequency. At week 14, post-RT treatment with BIO 300 resulted in significantly higher quality of erectile function compared with both the RT arm and the RT arm receiving genistein starting 3 days before irradiation (P.05). In hormone-sensitive and insensitive prostate tumor-bearing mice, BIO 300 administration did not negatively affect radiation-induced tumor growth delay.BIO 300 prevents radiation-induced ED, measured by erection frequency, erectile function, and erection quality, when administered 3 days before RT and continued daily for up to 14 weeks. Data also suggest that BIO 300 administered starting 2 hours after RT mitigates radiation-induced ED. Data provide strong nonclinical evidence to support clinical translation of BIO 300 for mitigation of ED while maintaining treatment response to RT.
- Published
- 2019
6. Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial
- Author
-
Nicolas Girard, Jonathan Spicer, Mariano Provencio, Shun Lu, Stephen Broderick, Mark M. Awad, Tetsuya Mitsudomi, Keith Kerr, Julie Brahmer, Scott J. Swanson, Enriqueta Felip, Changli Wang, Gene B. Saylors, Ke-Neng Chen, Fumihiro Tanaka, Moishe Liberman, Cecile Dorange, Javed Mahmood, Junliang Cai, and Patrick M. Forde
- Subjects
Cancer Research ,Oncology - Abstract
Background: CheckMate 816 (NCT02998528), a randomized phase 3 study of neoadjuvant NIVO + chemo vs chemo for resectable NSCLC, met its first primary endpoint with a statistically significant improvement in pathological complete response (pCR) rate (24% vs 2%; odds ratio 13.94 [99% CI, 3.49-55.75; P < 0.0001]). pCR benefit was consistent across key subgroups, including disease stages, histologies, and PD-L1 expression levels. Notably, neoadjuvant NIVO + chemo did not impede feasibility of surgery nor increase incidence of surgical complications or adverse events (AEs) vs chemo alone. We report results from the first prespecified interim analysis of EFS, the other primary endpoint. Methods: Adults with stage IB (≥ 4 cm)-IIIA (per AJCC 7th ed) resectable NSCLC, ECOG PS ≤ 1, and no known EGFR/ALK alterations were randomized to NIVO 360 mg + chemo Q3W or chemo Q3W for 3 cycles (n = 179 each). Primary endpoints were EFS and pCR (both assessed by blinded independent review) in the randomized population. EFS was defined as the length of time from randomization to any disease progression precluding surgery, disease progression or recurrence after surgery, or death due to any cause. An exploratory analysis of EFS by pCR status was conducted. Results: At a median follow-up of 29.5 mo (database lock, October 20, 2021), neoadjuvant NIVO + chemo significantly improved EFS vs chemo in the randomized population (median [95% CI], 31.6 mo [30.2-not reached (NR)] vs 20.8 mo [14.0-26.7]; HR [97.38% CI], 0.63 [0.43-0.91]; P = 0.0052; 2-year EFS rates, 64% vs 45%). EFS results in the subgroups by disease stages, histologies, and PD-L1 expression levels are shown in the Table: In the pooled patient population (NIVO + chemo and chemo arms combined), EFS was improved in patients with pCR compared with those without (median, NR vs 21.1 mo; HR [95% CI], 0.11 [0.04-0.29]). Incidence of grade 3-4 treatment-related (33.5% vs 36.9%) and surgery-related AEs (11.4% vs 14.8%) was similar between the NIVO + chemo and chemo arms, as reported previously. Conclusions: In CheckMate 816, neoadjuvant NIVO + chemo showed a statistically significant and clinically meaningful improvement in EFS vs chemo alone. These results, along with the significant improvement in pCR, support NIVO + chemo as a potential new treatment option for patients with stage IB-IIIA resectable NSCLC. Subgroups Median EFS, mo (95% CI) HR (95% CI) NIVO + chemo Chemo Overall (n = 358) 31.6 (30.2-NR) 20.8 (14.0-26.7) 0.63 (0.43-0.91)a Baseline disease stage IB-II (n = 127) NR (27.8-NR) NR (16.8-NR) 0.87 (0.48-1.56) IIIA (n = 228) 31.6 (26.6-NR) 15.7 (10.8-22.7) 0.54 (0.37-0.80) Tumor histology Squamous (n = 182) 30.6 (20.0-NR) 22.7 (11.5-NR) 0.77 (0.49-1.22) Non-squamous (n = 176) NR (27.8-NR) 19.6 (13.8-26.2) 0.50 (0.32-0.79) PD-L1 expression level < 1% (n = 155) 25.1 (14.6-NR) 18.4 (13.9-26.2) 0.85 (0.54-1.32) ≥ 1% (n = 178) NR (NR-NR) 21.1 (11.5-NR) 0.41 (0.24-0.70) 1-49% (n = 98) NR (27.8-NR) 26.7 (11.5-NR) 0.58 (0.30-1.12) ≥ 50% (n = 80) NR (NR-NR) 19.6 (8.2-NR) 0.24 (0.10-0.61) a97.38% CI reported. Chemo, chemotherapy; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; mo, months; NIVO, nivolumab; NR, not reached; PD-L1, programmed death ligand 1. Citation Format: Nicolas Girard, Jonathan Spicer, Mariano Provencio, Shun Lu, Stephen Broderick, Mark M. Awad, Tetsuya Mitsudomi, Keith Kerr, Julie Brahmer, Scott J. Swanson, Enriqueta Felip, Changli Wang, Gene B. Saylors, Ke-Neng Chen, Fumihiro Tanaka, Moishe Liberman, Cecile Dorange, Javed Mahmood, Junliang Cai, Patrick M. Forde. Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr CT012.
- Published
- 2022
7. A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice
- Author
-
Javed Mahmood, Allen A. Alexander, Santanu Samanta, Shriya Kamlapurkar, Prerna Singh, Ali Saeed, France Carrier, Xuefang Cao, Hem D Shukla, and Zeljko Vujaskovic
- Subjects
0301 basic medicine ,Cancer Research ,medicine.medical_treatment ,pancreatic cancer ,lcsh:RC254-282 ,radiation therapy ,Article ,03 medical and health sciences ,0302 clinical medicine ,Pancreatic tumor ,Anti-OX40 ,Pancreatic cancer ,medicine ,Survival rate ,Chemotherapy ,business.industry ,Cancer ,Immunotherapy ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,hyperthermia ,Radiation therapy ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer research ,combination treatment ,immunotherapy ,Cell activation ,business - Abstract
Background: Pancreatic cancer (PC) is the fourth-most-deadly cancer in the United States with a 5-year survival rate of only 8%. Unfortunately, only 10&ndash, 20% of PC patients are candidates for surgery, with the vast majority of patients with locally-advanced disease undergoing chemotherapy and/or radiation therapy (RT). Current treatments are clearly inadequate and novel strategies are crucially required. We investigated a novel tripartite treatment (combination of tumor targeted hyperthermia (HT), radiation therapy (RT), and immunotherapy (IT)) to alter immunosuppressive PC-tumor microenvironment (TME). (2). Methods: In a syngeneic PC murine tumor model, HT was delivered before tumor-targeted RT, by a small animal radiation research platform (SARRP) followed by intraperitoneal injections of cytotoxic T-cell agonist antibody against OX40 (also known as CD134 or Tumor necrosis factor receptor superfamily member 4, TNFRSF4) that can promote T-effector cell activation and inhibit T-regulatory (T-reg) function. (3). Results: Tripartite treatment demonstrated significant inhibition of tumor growth (p <, 0.01) up to 45 days post-treatment with an increased survival rate compared to any monotherapy. Flow cytometric analysis showed a significant increase (p <, 0.01) in cytotoxic CD8 and CD4+ T-cells in the TME of the tripartite treatment groups. There was no tripartite-treatment-related toxicity observed in mice. (4). Conclusions: Tripartite treatment could be a novel therapeutic option for PC patients.
- Published
- 2020
8. Therapeutic Efficacy of Variable Biological Effectiveness of Proton Therapy in U-CH2 and MUG-Chor1 Human Chordoma Cell Death
- Author
-
Prerna Singh, John Eley, Nayab Mahmood, Binny Bhandary, Tijana Dukic, Kevin J. Tu, Jerimy Polf, Narottam Lamichhane, Javed Mahmood, Zeljko Vujaskovic, and Hem D. Shukla
- Subjects
musculoskeletal diseases ,Cancer Research ,linear energy transfer ,chordoma ,proton beam radiation ,Middle of the Spread-Out Bragg Peak (M-SOBP) ,End of the Spread-Out Bragg Peak (E-SOBP) ,radiobiological effectiveness ,radioresistance ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Article ,Oncology ,RC254-282 - Abstract
Simple Summary Chordoma is a rare, slow-growing cancer of the spinal cord. Photon radiation therapy and surgery are the standard of care for chordoma. Proton radiation therapy has become an increasingly common treatment in comparison to photon radiation therapy due to the ability to reduce off-target radiation dose. However, there is still an increased risk of toxicity to the surrounding critical structures that lead to poor treatment outcomes. Moreover, the biologic effectiveness of protons to sterilize chordoma cells remains uncertain and likely varies according to the proton energy spectrum throughout the proton field. We aim to investigate the tumoricidal properties of proton radiation therapy at the middle and end of the proton radiation field and elucidate variations in the relative biological effectiveness for chordoma cells. Our study helps quantify the therapeutic value of treating chordoma near the end of the proton field, where linear energy transfer is relatively high. Abstract Background: Chordoma is a cancer of spinal cord, skull base, and sacral area. Currently, the standard of care to treat chordoma is resection followed by radiation therapy. Since, chordoma is present in the spinal cord and these are very sensitive structures and often complete removal by surgery is not possible. As a result, chordoma has a high chance of recurrence and developing resistance to radiation therapy. In addition, treatment of chordoma by conventional radiation therapy can also damage normal tissues surrounding chordoma. Thus, current therapeutic options to treat chordoma are insufficient and novel therapies are desperately needed to treat locally advanced and metastatic chordoma. (2) Methods: In the present investigation, human chordoma cell lines of sacral origin MUG-Chor1 and U-CH2 were cultured and irradiated with Proton Beam Radiation using the clinical superconducting cyclotron and pencil-beam (active) scanning at Middle and End of the Spread-Out Bragg Peak (SOBP). Proton radiation was given at the following doses: Mug-Chor1 at 0, 1, 2, 4, and 8 Gy and U-CH2 at 0, 4, 8, 12, and 16 Gy. These doses were selected based on a pilot study in our lab and attempted to produce approximate survival fractions in the range of 1, 0.9, 0.5, 0.1, and 0.01, respectively, chosen for linear quadratic model fitting of the dose response. (3) Results: In this study, we investigated relative biological effectiveness (RBE) of proton radiation at the end of Spread Out Bragg Peak assuming that the reference radiation is a proton radiation in the middle of the SOBP. We observed differences in the survival of both Human chordoma cell lines, U-CH2 and MUG-Chor1. The data showed that there was a significantly higher cell death at the end of the Bragg peak as compared to middle of the Bragg peak. Based on the linear quadratic (LQ) fit for cell survival we calculated the RBE between M-SOBP and E-SOBP at 95% CI level and it was observed that RBE was higher than 1 at E-SOBP and caused significantly higher cell killing. Proton field at E-SOBP caused complex DNA damage in comparison to M-EOBP and the genes such as DNA topoisomerase 1, GTSE1, RAD51B were downregulated in E-SOBP treated cells. Thus, we conclude that there seems to be substantial variation in RBE (1.3–1.7) at the E-SOBP compared with the M-SOBP.
- Published
- 2021
9. Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer
- Author
-
Zeljko Vujaskovic, Santanu Samanta, John Eley, Javed Mahmood, Binny Bhandary, Sanjit K. Roy, Tijana Dukic, Hem D. Shukla, Dominic Leiser, Minjie Chen, M. Creed, Paul N. Staats, Tami J. Kingsbury, and Josh Strauss
- Subjects
Lung Neoplasms ,DNA Repair ,medicine.medical_treatment ,Caveolin 1 ,Cancer Treatment ,Gene Dosage ,Gene Expression ,Treatment of lung cancer ,Radiation Tolerance ,Lung and Intrathoracic Tumors ,Medicine and Health Sciences ,Protein Interaction Maps ,Mice, Inbred BALB C ,Multidisciplinary ,Adenocarcinoma of the Lung ,Animal Models ,Prognosis ,Up-Regulation ,Gene Expression Regulation, Neoplastic ,Oncology ,Experimental Organism Systems ,Carcinoma, Squamous Cell ,Neoplastic Stem Cells ,Medicine ,Research Article ,Clinical Oncology ,Science ,Radiation Therapy ,Mice, Nude ,Mouse Models ,Adenocarcinoma ,Research and Analysis Methods ,Model Organisms ,Cancer stem cell ,Radioresistance ,Genetics ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Neoplasm Invasiveness ,Lung cancer ,Tumor microenvironment ,business.industry ,Gene Expression Profiling ,Carcinoma ,Cancers and Neoplasms ,Biology and Life Sciences ,Microarray Analysis ,medicine.disease ,Xenograft Model Antitumor Assays ,Non-Small Cell Lung Cancer ,Radiation therapy ,A549 Cells ,Tumor progression ,Cancer cell ,Animal Studies ,Cancer research ,Clinical Medicine ,Secondary Lung Tumors ,business - Abstract
Radiation therapy plays a major role in the treatment of lung cancer patients. However, cancer cells develop resistance to radiation. Tumor radioresistance is a complex multifactorial mechanism which may be dependent on DNA damage and repair, hypoxic conditions inside tumor microenvironment, and the clonal selection of radioresistant cells from the heterogeneous tumor site, and it is a major cause of treatment failure in non–small cell lung cancer (NSCLC). In the present investigation caveolin-1 (CAV-1) has been observed to be highly expressed in radiation resistant A549 lung cancer cells. CRISPR-Cas9 knockout of CAV-1 reverted the cells to a radio sensitive phenotype. In addition, CAV-1 overexpression in parental A549 cells, led to radiation resistance. Further, gene expression analysis of A549 parental, radiation resistant, and caveolin-1 overexpressed cells, exhibited overexpression of DNA repair genes RAD51B, RAD18, SOX2 cancer stem cell marker, MMPs, mucins and cytoskeleton proteins in resistant and caveolin-1 over expressed A549 cells, as compared to parental A549 cells. Bioinformatic analysis shows upregulation of BRCA1, Nuclear Excision DNA repair, TGFB and JAK/STAT signaling pathways in radioresistant and caveolin-1 overexpressed cells, which may functionally mediate radiation resistance. Immunohistochemistry data demonstrated heterogeneous expression of CAV-1 gene in human lung cancer tissues, which was analogous to its enhanced expression in human lung cancer cell line model and mouse orthotopic xenograft lung cancer model. Also, TCGA PanCancer clinical studies have demonstrated amplification, deletions and missense mutation in CAV-1 gene in lung cancer patients, and that CAV-1 alteration has been linked to poor prognosis, and poor survival in lung cancer patients. Interestingly, we have also optimized ELISA assay to measure caveolin-1 protein in the blood of A549 radiation resistant human xenograft preclinical mouse model and discovered higher level of caveolin-1 (950 pg/ml) in tumor bearing animals treated with radiation, as compared to xenograft with radiosensitive lung cancer cells (450 pg/ml). Thus, we conclude that caveolin-1 is involved in radio-resistance and contributes to tumor aggression, and it has potential to be used as prognostic biomarker for radiation treatment response, and tumor progression for precision medicine in lung cancer patients.
- Published
- 2021
10. Investigating chemopotentiation by low-dose fractionated radiation therapy for disseminated intra-abdominal gastric cancer
- Author
-
France Carrier, Palak Parekh, Eduardo Solano-Gonzalez, Xinrong Ma, Kayla Tighe, Andrea Casildo, Andrew Zodda, Christopher Johnstone, Yannick Poirier, Javed Mahmood, Kavita Bhalla, Sheri Li, and Rena G. Lapidus
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,Low dose ,Cancer ,Treatment options ,Disease ,medicine.disease ,Oncology ,Medicine ,Radiology ,Gastrointestinal cancer ,business ,Fractionated radiation - Abstract
242 Background: Treatment options are rather limited for gastrointestinal cancer patients whose disease has disseminated into the intra-abdominal cavity. There is currently no modality that has been shown to prolong survival of this patient sub-population. Here, we designed pre-clinical studies to evaluate the potential application of chemopotentiation by Low Dose Fractionated Radiation Therapy (LDFRT) for disseminated gastric cancer and evaluate the role of a likely biomarker, the Dual Oxidase 2 (DUOX2) enzyme. Methods: Nude mice were injected orthotopically with human gastric cancer cells expressing endogenous or lower levels of DUOX2 and randomly assigned to four treatment groups: 1; vehicle alone, 2; chemotherapy consisting of a modified regimen of docetaxel, cisplatin and 5’-fluorouracil (mDCF) for three consecutive days, 3; Low Dose- Whole Abdomen Radiation Therapy (LD-WART) (5 fractions of 15 cGy in three days), 4; mDCF and LD-WART. Blood was harvested at day 14 and 45 and cancer progression was evaluated by fluorescence imaging (Xenogen). Results: The combined regimen was well tolerated in all animals and led to DUOX2 upregulation, increased serum protein oxidation and reduced cancer progression in the DUOX2 positive tumors. Tumors expressing lower DUOX2 levels were more sensitive to chemotherapy but no additional benefit was obtained with LD-WART. The potential clinical significance of these findings is exemplified by a tumor microarray demonstrating that only about 46% of human gastric tumors expressed DUOX2. The molecular mechanisms underlying DUOX2 effects in response to the combined regimen include NF-kB upregulation and VEGF down regulation. Moreover, the combined regimen of mDCF and LDFRT was also effective on a Cancer Stem Cell (CSC)-Like subpopulation of mouse gastric cancer cells. Conclusions: Taken together these data suggest that DUOX2 could be used as a potential biomarker for patient stratification for chemopotentiation by LD-WART for positive tumors while chemotherapy alone would be more effective for DUOX2 negative tumors. The absence of added toxicity suggests that these cycles could be repeated.
- Published
- 2021
11. Hyperthermia Induces Radiosensitization and Leads to Reduced Brachyury Levels in Chordoma Cells
- Author
-
Zeljko Vujaskovic, A. Saeed, P. Singh, R.S. Malyapa, and Javed Mahmood
- Subjects
Hyperthermia ,Cancer Research ,Brachyury ,Radiation ,Oncology ,business.industry ,Cancer research ,medicine ,Radiology, Nuclear Medicine and imaging ,Chordoma ,medicine.disease ,business - Published
- 2020
12. Caveolin-1: a novel prognostic biomarker of radioresistance in cancer
- Author
-
Stephanie C Murti, Allen A. Alexander, Zeljko Vujaskovic, Javed Mahmood, Caroline Q. Connors, Sarthak R Zaveri, and Hem D. Shukla
- Subjects
0301 basic medicine ,Oncology ,medicine.medical_specialty ,medicine.medical_treatment ,Caveolin 1 ,Biology ,Radiation Tolerance ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Neoplasms ,Internal medicine ,Radioresistance ,Biomarkers, Tumor ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Clinical significance ,Evidence-Based Medicine ,Radiological and Ultrasound Technology ,Cancer ,Prognosis ,medicine.disease ,Gene Expression Regulation, Neoplastic ,Radiation therapy ,Treatment Outcome ,030104 developmental biology ,Tumor progression ,030220 oncology & carcinogenesis ,Biomarker (medicine) - Abstract
Caveolin-1 is a membrane protein highly expressed in many tumors and plays an important role in tumor progression and metastasis. This review describes the structure of the Caveolin-1 protein and its pre-clinical and clinical significance, demonstrating that Caveolin-1 is a novel biomarker for radioresistance which has the promising potential to improve the clinical outcome of cancer patients undergoing radiation treatment.Targeted radiation therapy has shown immense benefits for cancer treatment. However, one of the major challenges for effective clinical outcome of radiation therapy for cancer patients is the development of radioresistance during radiation treatment. As a consequence, radiation therapy becomes a less effective modality for successful clinical outcome. Furthermore, a radioresistant tumor has the ability to repair its genome, and therefore becomes more aggressive and metastasizes. The plausible mechanisms for tumor radioresistance include the rapid DNA repair, somatic mutations in tumor oncogenes, aberrant activation of kinase pathways, and changes in the tumor microenvironment including tumor hypoxia, tumor vasculature, and cancer stem cells. Caveolin-1 is significantly upregulated in certain cancer cells and aberrantly mediates downstream signaling mechanisms. Notably, numerous recent research reports have shown the role of Caveolin-1 in tumor radioresistance and poor treatment outcome. Thus, Caveolin-1 could be a novel prognostic biomarker to monitor tumor radioresistance in cancer patients undergoing radiation therapy.Caveolin-1 has the promising potential to become a novel prognostic biomarker to monitor tumor radioresistance and radiation response specifically in the prostate, pancreas, and lung cancer.
- Published
- 2016
13. Integrated proteo-genomic approach for early diagnosis and prognosis of cancer
- Author
-
Hem D. Shukla, Javed Mahmood, and Zeljko Vujaskovic
- Subjects
Proteomics ,Cancer Research ,Proteome ,Biology ,Bioinformatics ,medicine.disease_cause ,Radiation Tolerance ,Metastasis ,Germline mutation ,Neoplasms ,Biomarkers, Tumor ,medicine ,Humans ,Copy-number variation ,Precision Medicine ,Survival rate ,Early Detection of Cancer ,business.industry ,Prognosis ,Proteogenomics ,Precision medicine ,medicine.disease ,Oncology ,Personalized medicine ,business ,Carcinogenesis - Abstract
Cancer is the leading cause of mortality among men and women worldwide. Despite the availability of numerous diagnostic techniques for various cancers, the overall survival rate remains low and the majority of patients die due to late diagnosis and advanced stage of the disease. Diagnosing and treating cancer at its early stages ideally during the precancerous phase could significantly increase survival rate with the possibility of cure and prolong survival. Cancer is a genetic disease and it is illicitly activated by the acquisition of somatic DNA lesions and aberrations in genome structure and defects in maintenance and repair. These somatic DNA mutations known as driver mutations seem to be the prime cause in initiating tumorigenesis. The advances in genomic technologies have immensely facilitated the understanding of cancer progression and metastasis, and the discovery of novel biomarkers. However, changes in somatic mutational landscape of the oncogenome are translated into aberrantly regulated oncoproteome which drives the cancer initiation. Thus, combination of proteomic and genomic technologies is urgently required to discover biomarkers for early diagnosis. The recent advances in human genome based detection of cancer using advanced genomic technologies like NextGen Sequencing, digital PCR, cfDNA technology have shown promise; for example oncogenic somatic mutation variants, transcriptomic analysis, copy number variant, and methylation data from the Cancer Genome Atlas. Similarly, oncoproteomics has the potential to revolutionize clinical management of the disease, including cancer diagnosis and screening based on new proteomic database which embodies somatic variants and post translational modifications, thus devising proteomic technologies as a complement to histopathology. Further, the use of multiple proteomic and genomic biomarkers rather than a single gene or protein could greatly improve diagnostic accuracy and enhance the predictive power for treatment outcome and may enable adequate monitoring of the response to treatment and could be an important option for personalized medicine. The proteogenomic approach has the promise to identify new biomarkers for radiation therapy (RT) which could reliably predict the tumor radiation resistance and which could also accurately predict normal tissue toxicity, and at the same time radiotherapy effectiveness. In this review we have summarize the recent advances in proteogenomic approaches to develop more sensitive diagnostic and prognostic biomarkers which could be translated into improved clinical care and management of the disease.
- Published
- 2015
14. Immunotherapy, Radiotherapy, and Hyperthermia: A Combined Therapeutic Approach in Pancreatic Cancer Treatment
- Author
-
Santanu Samanta, Sandrine Soman, Zeljko Vujaskovic, Ali Saeed, Prerna Singh, Hem D. Shukla, Javed Mahmood, Shriya Kamlapurkar, and Neha P. Amin
- Subjects
0301 basic medicine ,Hyperthermia ,Cancer Research ,medicine.medical_treatment ,pancreatic cancer ,Review ,lcsh:RC254-282 ,radiation therapy ,Metastasis ,03 medical and health sciences ,tripartite ,0302 clinical medicine ,Pancreatic cancer ,Medicine ,metastasis ,tumor microenvironment ,targeted hyperthermia ,Tumor microenvironment ,Chemotherapy ,business.industry ,Immunotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Radiation therapy ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,immunotherapy ,business - Abstract
Pancreatic cancer (PC) has the highest mortality rate amongst all other cancers in both men and women, with a one-year relative survival rate of 20%, and a five-year relative survival rate of 8% for all stages of PC combined. The Whipple procedure, or pancreaticoduodenectomy, can increase survival for patients with resectable PC, however, less than 20% of patients are candidates for surgery at time of presentation. Most of the patients are diagnosed with advanced PC, often with regional and distant metastasis. In these advanced cases, chemotherapy and radiation have shown limited tumor control, and PC continues to be refractory to treatment and results in a poor survival outcome. In recent years, there has been intensive research on checkpoint inhibitor immunotherapy for PC, however, PC is characterized with dense stromal tissue and a tumor microenvironment (TME) that is highly immunosuppressive, which makes immunotherapy less effective. Interestingly, when immunotherapy is combined with radiation therapy (RT) and loco-regional hyperthermia (HT), it has demonstrated enhanced tumor responses. HT improves tumor killing via a variety of mechanisms, targeting both the tumor and the TME. Targeted HT raises the temperature of the tumor and surrounding tissues to 42–43 °C and makes the tumor more immunoresponsive. HT can also modulate the immune system of the TME by inducing and synthesizing heat shock proteins (HSP), which also activate an anti-tumor response. It is well known that HT can enhance RT-induced DNA damage in cancer cells and simultaneously help to oxygenate hypoxic regions. Thus, it is envisaged that combined HT and RT might have immunomodulatory effects in the PC-TME, making PC more responsive to immunotherapies. Moreover, the combined tripartite approach of immunotherapy, RT, and HT could reduce the overall toxicity associated with each individual therapy, while concomitantly enhancing the immunotherapeutic effect of overall individual therapies to treat local and metastatic PC. Thus, the use of a tripartite combinatorial approach could be promising and more efficacious than monotherapy or dual therapy to treat and increase the survival of the PC patients.
- Published
- 2018
15. RhoA/ROCK Pathway Inhibitor Ameliorates Radiation-induced Erectile Dysfunction in Rats
- Author
-
Zeljko Vujaskovic, L. Dominic, J. Strauss, and Javed Mahmood
- Subjects
Cancer Research ,Radiation ,RHOA ,biology ,business.industry ,Radiation induced ,Pharmacology ,medicine.disease ,Erectile dysfunction ,Oncology ,medicine ,biology.protein ,Radiology, Nuclear Medicine and imaging ,business - Published
- 2019
16. Radiation Therapy in Combination with Hyperthermia and Immunotherapy Inhibit Pancreatic Tumor Growth and Modulate Tumor Microenvironment in Mice
- Author
-
Javed Mahmood, Santanu Samanta, E. Davila, Isabel L. Jackson, Allen A. Alexander, Zeljko Vujaskovic, Hem D. Shukla, F. Carrier, and Sandrine Soman
- Subjects
Hyperthermia ,Cancer Research ,Tumor microenvironment ,Radiation ,business.industry ,medicine.medical_treatment ,Immunotherapy ,medicine.disease ,Radiation therapy ,Oncology ,Pancreatic tumor ,medicine ,Cancer research ,Radiology, Nuclear Medicine and imaging ,business - Published
- 2018
17. CRISPR Cas9 Mediated Caveolin-1 Knockout Sensitizes Radioresistant Non-Small Cell Lung Cancer
- Author
-
Santanu Samanta, Hem D. Shukla, Javed Mahmood, Sandrine Soman, J. Eley, T. Kingsbury, Allen A. Alexander, M. Creed, Amit Sawant, and Zeljko Vujaskovic
- Subjects
Cancer Research ,Radiation ,business.industry ,medicine.disease ,Oncology ,Radioresistance ,Caveolin 1 ,Cancer research ,Medicine ,CRISPR ,Radiology, Nuclear Medicine and imaging ,Non small cell ,business ,Lung cancer - Published
- 2018
18. Novel Strategy to Develop Orthotopic Prostate Tumor using Androgen Dependent LNCaP Transduced with miR133b
- Author
-
Santanu Samanta, Akbar Anvari, T. Kingsbury, M. Creed, Javed Mahmood, and Amit Sawant
- Subjects
Cancer Research ,Androgen dependent ,Radiation ,medicine.anatomical_structure ,Oncology ,Prostate ,business.industry ,LNCaP ,medicine ,Cancer research ,Radiology, Nuclear Medicine and imaging ,business - Published
- 2018
19. Targeting the Renin–Angiotensin System Combined With an Antioxidant Is Highly Effective in Mitigating Radiation-Induced Lung Damage
- Author
-
Richard P. Hill, Susan R. Doctrow, Salomeh Jelveh, Asif Zaidi, Meetha Medhora, and Javed Mahmood
- Subjects
Cancer Research ,medicine.medical_specialty ,Captopril ,Radiation-Protective Agents ,Thiobarbituric Acid Reactive Substances ,Article ,Rats, Sprague-Dawley ,Renin-Angiotensin System ,Transforming Growth Factor beta1 ,Lipid peroxidation ,Hydroxyproline ,chemistry.chemical_compound ,Subcutaneous injection ,Respiratory Rate ,Fibrosis ,Internal medicine ,Renin–angiotensin system ,Organometallic Compounds ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Lung ,Radiation ,business.industry ,Deoxyguanosine ,medicine.disease ,Malondialdehyde ,Rats ,Radiation Pneumonitis ,Radiation Injuries, Experimental ,Endocrinology ,medicine.anatomical_structure ,Oncology ,chemistry ,8-Hydroxy-2'-Deoxyguanosine ,Drug Therapy, Combination ,Female ,Lipid Peroxidation ,business ,DNA Damage ,medicine.drug - Abstract
Purpose To investigate the outcome of suppression of the renin angiotensin system using captopril combined with an antioxidant (Eukarion [EUK]-207) for mitigation of radiation-induced lung damage in rats. Methods and Materials The thoracic cavity of female Sprague-Dawley rats was irradiated with a single dose of 11 Gy. Treatment with captopril at a dose of 40 mg/kg/d in drinking water and EUK-207 given by subcutaneous injection (8 mg/kg daily) was started 1 week after irradiation (PI) and continuing until 14 weeks PI. Breathing rate was monitored until the rats were killed at 32 weeks PI, when lung fibrosis was assessed by lung hydroxyproline content. Lung levels of the cytokine transforming growth factor-β1 and macrophage activation were analyzed by immunohistochemistry. Oxidative DNA damage was assessed by 8-hydroxy-2-deoxyguanosine levels, and lipid peroxidation was measured by a T-BARS assay. Results The increase in breathing rate in the irradiated rats was significantly reduced by the drug treatments. The drug treatment also significantly decreased the hydroxyproline content, 8-hydroxy-2-deoxyguanosine and malondialdehyde levels, and levels of activated macrophages and the cytokine transforming growth factor-β1 at 32 weeks. Almost complete mitigation of these radiation effects was observed by combining captopril and EUK-207. Conclusion Captopril and EUK-207 can provide mitigation of radiation-induced lung damage out to at least 32 weeks PI after treatment given 1-14 weeks PI. Overall the combination of captopril and EUK-207 was more effective than the individual drugs used alone.
- Published
- 2014
20. Mild hyperthermia as a localized radiosensitizer for deep-seated tumors: investigation in an orthotopic prostate cancer model in mice
- Author
-
Zeljko Vujaskovic, Yannick Poirier, Allen A. Alexander, Sandrine Soman, Amit Sawant, Ramilda Pavlovic, Maida Ranjbar, Akbar Anvari, Justin Cohen, Santanu Samanta, Andrew Zodda, Javed Mahmood, and Isabel L. Jackson
- Subjects
Male ,Oncology ,Hyperthermia ,Radiation-Sensitizing Agents ,medicine.medical_specialty ,Radiosensitizer ,medicine.medical_treatment ,Blotting, Western ,Mice, Nude ,Apoptosis ,030218 nuclear medicine & medical imaging ,Mice ,Random Allocation ,03 medical and health sciences ,Mild hyperthermia ,Prostate cancer ,0302 clinical medicine ,Internal medicine ,medicine ,Animals ,Combined Modality Therapy ,Radiology, Nuclear Medicine and imaging ,Caspase 3 ,business.industry ,Radiotherapy Planning, Computer-Assisted ,Prostatic Neoplasms ,Hyperthermia, Induced ,General Medicine ,medicine.disease ,Caspase 9 ,Radiation therapy ,Clinical trial ,Disease Models, Animal ,Small animal IGRT special feature: Full paper ,Tomography, X-Ray Computed ,business ,Radiotherapy, Image-Guided - Abstract
OBJECTIVE: Non-ablative or mild hyperthermia (HT) has been shown in preclinical (and clinical) studies as a localized radiosensitizer that enhances the tumoricidal effects of radiation. Most preclinical in vivo HT studies use subcutaneous tumor models which do not adequately represent clinical conditions (e.g. proximity of normal/critical organs) or replicate the tumor microenvironment—both of which are important factors for eventual clinical translation. The purpose of this work is to demonstrate proof-of-concept of locoregional radiosensitization with superficially applied, radiofrequency (RF)-induced HT in an orthotopic mouse model of prostate cancer. METHODS: In a 4-arm study, 40 athymic male nude mice were inoculated in the prostate with luciferase-transfected human prostate cancer cells (PC3). Tumor volumes were allowed to reach 150–250 mm(3) (as measured by ultrasound) following which, mice were randomized into (i) control (no intervention); (ii) HT alone; (iii) RT alone; and (iv) HT + RT. RF-induced HT was administered (Groups ii and iv) using the Oncotherm LAB EHY-100 device to achieve a target temperature of 41 °C in the prostate. RT was administered ~30 min following HT, using an image-guided small animal radiotherapy research platform. In each case, a dual arc plan was used to deliver 12 Gy to the target in a single fraction. One animal from each cohort was euthanized on Day 10 or 11 after treatment for caspase-9 and caspase-3 Western blot analysis. RESULTS: The inoculation success rate was 89%. Mean tumor size at randomization (~16 days post-inoculation) was ~189 mm(3) . Following the administration of RT and HT, mean tumor doubling times in days were: control = 4.2; HT = 4.5; RT = 30.4; and HT + RT = 33.4. A significant difference (p = 0.036) was noted between normalized nadir volumes for the RT alone (0.76) and the HT + RT (0.40) groups. Increased caspase-3 expression was seen in the combination treatment group compared to the other treatment groups. CONCLUSION: These early results demonstrate the successful use of external mild HT as a localized radiosensitizer for deep-seated tumors. ADVANCES IN KNOWLEDGE: We successfully demonstrated the feasibility of administering external mild HT in an orthotopic tumor model and demonstrated preclinical proof-of-concept of HT-based localized radiosensitization in prostate cancer radiotherapy.
- Published
- 2019
21. Radiation-induced erectile dysfunction: Recent advances and future directions
- Author
-
Radmila Pavlovic, Zeljko Vujaskovic, Isabel L. Jackson, Javed Mahmood, Jason K. Molitoris, Hem D. Shukla, Masaki Kimura, T. Michael Creed, Aksinija A. Shamah, and Hotaka Matsui
- Subjects
Oncology ,lcsh:Medical physics. Medical radiology. Nuclear medicine ,Pathology ,medicine.medical_specialty ,medicine.medical_treatment ,lcsh:R895-920 ,030232 urology & nephrology ,Radiogenomics ,lcsh:RC254-282 ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Germline mutation ,Prostate ,Internal medicine ,medicine ,Radiology, Nuclear Medicine and imaging ,Scientific Article ,business.industry ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Radiation therapy ,Erectile dysfunction ,Sexual dysfunction ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,medicine.symptom ,Stem cell ,business - Abstract
Prostate cancer is one of the most prevalent cancers and the second leading cause of cancer-related deaths in men in the United States. A large number of patients undergo radiation therapy (RT) as a standard care of treatment; however, RT causes erectile dysfunction (radiation-induced erectile dysfunction; RiED) because of late side effects after RT that significantly affects quality of life of prostate cancer patients. Within 5 years of RT, approximately 50% of patients could develop RiED. Based on the past and current research findings and number of publications from our group, the precise mechanism of RiED is under exploration in detail. Recent investigations have shown prostate RT induces significant morphologic arterial damage with aberrant alterations in internal pudendal arterial tone. Prostatic RT also reduces motor function in the cavernous nerve which may attribute to axonal degeneration may contributing to RiED. Furthermore, the advances in radiogenomics such as radiation induced somatic mutation identification, copy number variation and genome-wide association studies has significantly facilitated identification of biomarkers that could be used to monitoring radiation-induced late toxicity and damage to the nerves; thus, genomic- and proteomic-based biomarkers could greatly improve treatment and minimize arterial tissue and nerve damage. Further, advanced technologies such as proton beam therapy that precisely target tumor and significantly reduce off-target damage to vital organs and healthy tissues. In this review, we summarize recent advances in RiED research and novel treatment modalities for RiED. We also discuss the possible molecular mechanism involved in the development of RiED in prostate cancer patients. Further, we discuss various readily available methods as well as novel strategies such as stem cell therapies, shockwave therapy, nerve grafting with tissue engineering, and nutritional supplementations might be used to mitigate or cure sexual dysfunction following radiation treatment.
- Published
- 2016
22. Treatment With Nano-Genistein for the Prevention of Radiation-Induced Erectile Dysfunction
- Author
-
Javed Mahmood, Isabel L. Jackson, Radmila Pavlovic, Michael D. Kaytor, Allen A. Alexander, Angel Zhang, Zeljko Vujaskovic, and Caroline Q. Connors
- Subjects
Cancer Research ,Radiation ,business.industry ,Genistein ,Radiation induced ,Pharmacology ,medicine.disease ,chemistry.chemical_compound ,Erectile dysfunction ,Oncology ,chemistry ,medicine ,Radiology, Nuclear Medicine and imaging ,business - Published
- 2017
23. Investigations into the role of inflammation in normal tissue response to irradiation
- Author
-
Richard P. Hill, Asif Zaidi, Salomeh Jelveh, and Javed Mahmood
- Subjects
Pathology ,Genistein ,030218 nuclear medicine & medical imaging ,Rats, Sprague-Dawley ,Mice ,chemistry.chemical_compound ,0302 clinical medicine ,Lung ,Cells, Cultured ,Skin ,Mice, Knockout ,chemistry.chemical_classification ,Micronucleus Tests ,biology ,Chemistry ,Hematology ,3. Good health ,medicine.anatomical_structure ,Oncology ,030220 oncology & carcinogenesis ,Female ,Tumor necrosis factor alpha ,Radiodermatitis ,medicine.symptom ,medicine.medical_specialty ,DNA damage ,Inflammation ,Article ,Superoxide dismutase ,03 medical and health sciences ,Species Specificity ,Organometallic Compounds ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Pneumonitis ,Reactive oxygen species ,Superoxide Dismutase ,Tumor Necrosis Factor-alpha ,medicine.disease ,Rats ,Mice, Inbred C57BL ,Radiation Pneumonitis ,Disease Models, Animal ,Multivariate Analysis ,Linear Models ,biology.protein ,Reactive Oxygen Species ,DNA Damage - Abstract
Radiation-induced inflammation and production of reactive oxygen species (ROS) play a critical role in normal tissue response. In this study we have examined some aspects of these effects in lung and skin.The superoxide dismutase (SOD) catalase mimetic, EUK-207, and genistein, an isoflavone with anti-inflammatory properties, were given post-irradiation and micronuclei (MN) formation was determined in cells derived from irradiated lung and skin. Changes in breathing rate were measured using a plethysmograph following irradiation of C57Bl6 mice knocked out for tumor necrosis factor (TNF)-alpha or its receptors, TNFR1/2, or treated with endotoxin (lipopolysaccharide - LPS).Both EUK-207 and genistein given after irradiation caused a large reduction in MN levels observed in lung cells during 14 weeks post-irradiation but ceasing treatment resulted in a rebound in MN levels at 28 weeks post-irradiation. In contrast, treatment with EUK-207 was largely ineffective in reducing MN observed in skin cells post-irradiation. Knock-out of TNF-alpha resulted in a reduced increase in breathing rate (peak at 12 weeks post-irradiation) relative to wild-type and TNFR1/2 knock-out. Treatment with LPS 1 h post-irradiation also reduced the increase in breathing rate.The increase in MN in lung cells after treatment with EUK-207 or genistein was stopped suggests that continuing ROS production contributes to DNA damage in lung cells over prolonged periods. That this effect was not seen in skin suggests this mechanism is less prominent in this tissue. The reduced level of radiation pneumonitis (as monitored by breathing rate changes) in animals knocked out for TNF-alpha suggests that this cytokine plays a significant role in inducing inflammation in lung following irradiation. The similar effect observed following LPS given post-irradiation suggests the possibility that such treatment modifies the long-term cyclic inflammatory response following irradiation in lungs.
- Published
- 2011
24. In Vitro and In Vivo Studies of a New Class of Anticancer Molecules for Targeted Radiotherapy of Cancer
- Author
-
Jenny Warrington, Qing-Bin Lu, Robert G. Bristow, David A. Jaffray, Chun Rong Wang, Ning Ou, Qin Rong Zhang, Ali Vedadi, and Javed Mahmood
- Subjects
0301 basic medicine ,Cancer Research ,Radiation-Sensitizing Agents ,Targeted Radiotherapy ,medicine.medical_treatment ,Antineoplastic Agents ,Apoptosis ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Mouse xenograft ,In vivo ,Cell Line, Tumor ,Neoplasms ,Drug Discovery ,Medicine ,Animals ,Humans ,DNA Breaks, Double-Stranded ,Molecular Targeted Therapy ,Radiotherapy ,business.industry ,X-Rays ,Cancer ,Fibroblasts ,medicine.disease ,Combined Modality Therapy ,Xenograft Model Antitumor Assays ,In vitro ,3. Good health ,Tumor Burden ,Clinical trial ,Radiation therapy ,Disease Models, Animal ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Female ,business - Abstract
There is a compelling need to develop anticancer therapies that target cancer cells and tissues. Arising from innovative femtomedicine studies, a new class of non–platinum-based halogenated molecules (called FMD molecules) that selectively kill cancer cells and protect normal cells in treatments of multiple cancers has been discovered. This article reports the first observation of the radiosensitizing effects of such compounds in combination with ionizing radiation for targeted radiotherapy of a variety of cancers. We present in vitro and in vivo studies focused on combination with radiotherapy of cervical, ovarian, head and neck, and lung cancers. Our results demonstrate that treatments of various cancer cells in vitro and in vivo mouse xenograft models with such compounds led to enhanced efficiencies in radiotherapy, while the compounds themselves induced no or little radiotoxicity toward normal cells or tissues. These compounds are therefore effective radiosensitizers that can be translated into clinical trials for targeted radiotherapy of multiple types of cancer. This study also shows the potential of femtomedicine to bring breakthroughs in understanding fundamental biologic processes and to accelerate the discovery of novel drugs for effective treatment or prevention of a variety of cancers. Mol Cancer Ther; 15(4); 640–50. ©2016 AACR.
- Published
- 2015
25. Caveolin-1: A Novel Prognostic Biomarker for Radioresistance in Non-Small Cell Lung Carcinoma (NSCLC) and Prostate Cancer
- Author
-
S.C. Murti, Zeljko Vujaskovic, S.R. Zaveri, Hem D. Shukla, and Javed Mahmood
- Subjects
Oncology ,PCA3 ,Cancer Research ,medicine.medical_specialty ,Radiation ,Lung ,business.industry ,medicine.disease ,Prostate cancer ,medicine.anatomical_structure ,Internal medicine ,Radioresistance ,Caveolin 1 ,medicine ,Carcinoma ,Radiology, Nuclear Medicine and imaging ,Prognostic biomarker ,Non small cell ,business - Published
- 2016
26. Abstract 1422: Enhancing the therapeutic effects of PARP inhibitors in combination DNA methyl transferase inhibitors, using low doses of ionizing radiation in non small cell lung cancers
- Author
-
Javed Mahmood, Stephen B. Baylin, Rena G. Lapidus, Lora Stojanovic, Eun Yong Choi, Daniel Fontaine, Pratik K. Nagaria, Feyruz V. Rassool, and Christopher Biondi
- Subjects
Cancer Research ,Combination therapy ,business.industry ,Poly ADP ribose polymerase ,DNA Methyltransferase Inhibitor ,Decitabine ,Cancer ,medicine.disease ,Poly (ADP-Ribose) Polymerase Inhibitor ,Molecular biology ,Oncology ,In vivo ,medicine ,Cancer research ,business ,medicine.drug ,Combination drug - Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in the US. Treatment most commonly relies on ionizing radiation (IR) and platinum-based DNA damaging agents, but long-term survival is poor and patients tend to suffer chronic side-effects due to the high radiation dose to the surrounding normal tissues. Therefore, new treatments are needed that can be used in combination lower radiation doses. We have recently reported that low, non-cytotoxic doses Poly ADP ribose polymerase inhibitors (PARPi) Talazoparib in combination with DNA methyltransferase inhibitors (DNMTi) Decitabine (DAC) or azacytidine (AZA) significantly increase cytotoxicity in acute myeloid leukemia and breast cancer models in vitro and anti-tumor effects in vivo. Simultaneous administration of both inhibitors result in increased PARP binding in DNA, leading to higher levels of DNA double strand breaks (DSBs), yielding increased cytotoxicity, compared with each agent treatment alone. We first studied the efficacy of Talazoparib and AZA combination therapy in multiple NSCLC cell lines (A549, H358 and H838) in vitro through colony forming assays. Results showed, compared to single agent treatments, combination drug treatment significantly decreased colony formation. Cell viability was also significantly decreased with the drug combination in MTS assays (P Citation Format: Christopher Biondi, Daniel Fontaine, Lora Stojanovic, Pratik Nagaria, Rena Lapidus, Eun Yong Choi, Javed Mahmood, Stephen Baylin, Feyruz V. Rassool. Enhancing the therapeutic effects of PARP inhibitors in combination DNA methyl transferase inhibitors, using low doses of ionizing radiation in non small cell lung cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 1422. doi:10.1158/1538-7445.AM2017-1422
- Published
- 2017
27. Elucidation of the Molecular Mechanism of Radiation-Induced Erectile Dysfunction
- Author
-
Radmila Pavlovic, Isabel L. Jackson, Javed Mahmood, A.A. Shamah, Zeljko Vujaskovic, Masaki Kimura, J. Eley, M. Creed, and Hotaka Matsui
- Subjects
Cancer Research ,Radiation ,Erectile dysfunction ,Oncology ,business.industry ,medicine ,Molecular mechanism ,Radiology, Nuclear Medicine and imaging ,Radiation induced ,Pharmacology ,medicine.disease ,business - Published
- 2016
28. Effects of Lipopolysaccharide on the response of C57BL/6J mice to whole thorax irradiation
- Author
-
Asif Zaidi, Salomeh Jelveh, Javed Mahmood, and Richard P. Hill
- Subjects
Lipopolysaccharides ,medicine.medical_specialty ,Pathology ,Lipopolysaccharide ,Interleukin-1beta ,Radiation-Protective Agents ,Article ,chemistry.chemical_compound ,Hydroxyproline ,Mice ,Respiratory Rate ,Fibrosis ,Transforming Growth Factor beta ,Internal medicine ,Interleukin-1alpha ,medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,RNA, Messenger ,Interleukin 6 ,Lung ,Analysis of Variance ,Mice, Inbred C3H ,biology ,Interleukin-6 ,Tumor Necrosis Factor-alpha ,Respiratory infection ,Hematology ,Transforming growth factor beta ,Thorax ,medicine.disease ,Mice, Inbred C57BL ,Radiation Pneumonitis ,Radiation Injuries, Experimental ,medicine.anatomical_structure ,Endocrinology ,Oncology ,chemistry ,biology.protein ,Linear Models ,Tumor necrosis factor alpha ,Female ,Collagen ,Biomarkers - Abstract
Background and purpose Inflammatory and fibrogenic processes play a crucial role in the radiation-induced injury in the lung. The aim of the present study was to examine whether additive LPS exposure in the lung (to simulate respiratory infection) would affect pneumonitis or fibrosis associated with lung irradiation. Material and methods Wildtype C57Bl/6J (WT-C57) and TNFα, TNFR1 and TNFR2 knockout ( −/− ) mice, in C57Bl/6J background, were given whole thorax irradiation (10Gy) with or without post-irradiation intratracheal administration of LPS (50μg/mice). Functional deficit was examined by measuring breathing rate at various times after treatment. Real-time Reverse Transcription–Polymerase Chain Reaction (RT–PCR) and immunohistochemistry were used to analyze the protein expression and m-RNA of Interleukin-1 alpha (IL-1α), Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Tumour Necrosis Factor alpha (TNFα) and Transforming Growth Factor beta (TGFβ) in the lung at various times after treatment. Inflammatory cells were detected by Mac-3 (macrophages) and Toluidine Blue (mast cells) staining. Collagen content was estimated by hydroxyproline (total collagen) and Sircol assay (soluble collagen). Levels of oxidative damage were assessed by 8 - hydroxy-2-deoxyguanosine (8-OHdG) staining. Results LPS exposure significantly attenuated the breathing rate increases following irradiation of WT-C57, TNFR1 −/− and TNFR2 −/− mice and to a lesser extent in TNFα −/− mice. Collagen content was significantly reduced after LPS treatment in WT-C57, TNFR1 −/− and TNFα −/− mice and there was a trend in TNFR2 −/− mice. Similarly there were lower levels of inflammatory cells and cytokines in the LPS treated mice. Conclusions This study reveals a mitigating effect of early exposure to LPS on injury caused by irradiation on lungs of C57Bl mice. The results suggest that immediate infection post irradiation may not impact lung response negatively in radiation-accident victims, however, further studies are required in different animal models, and with specific infectious agents, to confirm and extend our findings.
- Published
- 2012
29. Genistein can mitigate the effect of radiation on rat lung tissue
- Author
-
Aimee R. Langan, Salomeh Jelveh, Richard P. Hill, Victoria L Calveley, Jacob Van Dyk, Ivan Yeung, and Javed Mahmood
- Subjects
Pathology ,medicine.medical_specialty ,DNA damage ,Biophysics ,Genistein ,Radiation-Protective Agents ,Pharmacology ,Biology ,medicine.disease_cause ,Thiobarbituric Acid Reactive Substances ,Article ,Proinflammatory cytokine ,Rats, Sprague-Dawley ,chemistry.chemical_compound ,Malondialdehyde ,medicine ,TBARS ,Animals ,Radiology, Nuclear Medicine and imaging ,Radiation Injuries ,Lung ,Pneumonitis ,Radiation ,Micronucleus Tests ,medicine.disease ,Immunohistochemistry ,Rats ,Oncology ,chemistry ,Micronucleus test ,Medical Biophysics ,Cytokines ,Female ,Sprague-Dawley ,Oxidative stress ,DNA Damage - Abstract
We investigated whether genistein could protect the lung from radiation-induced injury. We hypothesized that genistein would reduce the levels of inflammatory cytokines and ROS after irradiation and therefore lead to reduced DNA damage and functional deficits. Whole lungs of Sprague-Dawley rats were irradiated with 18 Gy at approximately 0.5 Gy/min. At 28 weeks a micronucleus assay was used to examine DNA damage and, using immunohistochemical analysis, expression of IL-1alpha, IL-1beta, IL-6, TNF-alpha and TGF-beta, macrophage activation, oxidative stress (8-OHdG) and collagen levels were measured. A TBARS assay was used to measure the level of malondialdehyde. Functional damage was assessed by measuring the breathing rate of the rats over the course of the experiment. The increase in breathing rate after irradiation was damped in rats receiving genistein during the phase of pneumonitis (6-10 weeks), and there was a 50-80-day delay in lethality in this group. Genistein treatment also decreased the levels of the inflammatory cytokines TNF-alpha, IL-1beta and TGF-beta and led to a reduction in collagen content, a reduction in 8-OHdG levels, and complete protection against DNA damage measured in surviving rats at 28 weeks after irradiation. These results demonstrates that genistein treatment can provide partial protection against the early (pneumonitis) effects of lung irradiation and reduce the extent of fibrosis, although not sufficiently to prevent lethality at the radiation dose used in this study.
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.